Your browser doesn't support javascript.
loading
[Artículo traducido] Los inhibidores selectivos de la IL23 son, en su mayoría, efectivos y seguros en pacientes con psoriasis y fallo previo a tratamientos biológicos anti IL-17. Una experiencia de práctica clínica real a 52 semanas / Anti-Interleukin 23 Biologic Are Mostly Effective and Safe in Psoriatic Patients Who Failed Anti-Interleukin 17. A Real-Life, Retrospective 52-Week Experience
Arroyo-Andrés, J; Falkenhain-López, D; Agud-Dios, M; Rivera-Díaz, R.
Affiliation
  • Arroyo-Andrés, J; Hospital Universitario 12 de Octubre. Department of Dermatology. Madrid. España
  • Falkenhain-López, D; Hospital Universitario 12 de Octubre. Department of Dermatology. Madrid. España
  • Agud-Dios, M; Hospital Universitario 12 de Octubre. Department of Dermatology. Madrid. España
  • Rivera-Díaz, R; Hospital Universitario 12 de Octubre. Department of Dermatology. Madrid. España
Actas dermo-sifiliogr. (Ed. impr.) ; 114(4): t363-t365, abr. 2023. tab, graf
Article in Es | IBECS | ID: ibc-219013
Responsible library: ES1.1
Localization: ES15.1 - BNCS
Subject(s)
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Psoriasis / Antibodies, Monoclonal, Humanized Limits: Adult / Female / Humans / Male Language: Es Journal: Actas dermo-sifiliogr. (Ed. impr.) Year: 2023 Document type: Article
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Psoriasis / Antibodies, Monoclonal, Humanized Limits: Adult / Female / Humans / Male Language: Es Journal: Actas dermo-sifiliogr. (Ed. impr.) Year: 2023 Document type: Article